| Bioactivity | NLRP3-IN-13 (Compound C77 in reference patent) is a selective and potent NLRP3 inhibitor (IC50: 2.1 μM). NLRP3-IN-13 inhibits NLRP3 andNLRC4 inflammasomes, and inhibits NLRP3-mediated IL-1β production. NLRP3-IN-13 also inhibits NLRP3 ATPase activity. NLRP3-IN-13 can be used in the research of neuroinflammatory disorders[1]. |
| Name | NLRP3-IN-13 |
| CAS | 1704638-35-6 |
| Formula | C19H15N3O3S |
| Molar Mass | 365.41 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Reference | [1]. Devita Robert, et al. Benzoxazolones as inhibitors of inflammasomes and their preparation. Patent. WO2022187804. |
NLRP3-IN-13
CAS: 1704638-35-6 F: C19H15N3O3S W: 365.41
NLRP3-IN-13 (Compound C77 in reference patent) is a selective and potent NLRP3 inhibitor (IC50: 2.1 μM). NLRP3-IN-13 in
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.